Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Matrix Mineralization
100%
Proton Pump Inhibitors
100%
PHOSPHO1
100%
In Vitro Biomineralization
100%
Inhibitory Effect
28%
Concentration-dependent
14%
IC50
14%
Ranitidine
14%
Cimetidine
14%
Fracture Risk
14%
Bone Loss
14%
Gastric Acid
14%
Skeletal Effects
14%
Primary Osteoblasts
14%
Phosphatase
14%
Pantoprazole
14%
Secondary Hyperparathyroidism
14%
Pharmacoepidemiology
14%
Nizatidine
14%
Intestinal Calcium Absorption
14%
Histamine-2 Receptor Antagonists (H2RA)
14%
Esomeprazole
14%
Bone Matrix
14%
Tissue-nonspecific Alkaline Phosphatase
14%
Famotidine
14%
Fragility Fracture
14%
Bone-specific
14%
Medicine and Dentistry
In Vitro
100%
Mineralization
100%
Proton-Pump Inhibitor
100%
Osteolysis
14%
Osteoblast
14%
IC50
14%
Phosphatase
14%
Secondary Hyperparathyroidism
14%
Ranitidine
14%
Pantoprazole
14%
Bone Matrix
14%
Calcium Absorption
14%
Nizatidine
14%
H2 Antagonist
14%
Famotidine
14%
Cimetidine
14%
Fragility Fracture
14%
Esomeprazole
14%
Pharmacology, Toxicology and Pharmaceutical Science
Proton Pump Inhibitor
100%
IC50
14%
Histamine H2 Receptor Antagonist
14%
Ranitidine
14%
Nizatidine
14%
Esomeprazole
14%
Cimetidine
14%
Fragility Fracture
14%
Pantoprazole
14%
Secondary Hyperparathyroidism
14%
Famotidine
14%
Phosphatase
14%